Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto and Keenan Research Centre for Biomedical Sciences of St. Michael's Hospital, Toronto, Canada.
University of Toronto, Division of Cardiology, St. Michael's Hospital, Toronto, Canada.
Clin Biochem. 2019 Nov;73:57-61. doi: 10.1016/j.clinbiochem.2019.07.013. Epub 2019 Jul 27.
Growth differentiation factor 15 (GDF15) is markedly increased in end-stage kidney disease and has been related to increased mortality in patients on dialysis. We hypothesized that kidney transplantation would decrease both GDF15 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and that GDF-15 decrease relates to post-kidney transplantation allograft function.
End-stage kidney disease patients on dialysis awaiting a living donor kidney transplantation (n = 39), and those expected to be on the deceased donor waitlist for at least 12 months (n = 43) were enrolled at three transplant centers. Serum GDF15 and NT-proBNP were measured at 0, 3, and 12 months post-kidney transplantation or post-enrollment. Change in serum GDF15 and NT-proBNP concentrations, and their relation to estimated glomerular filtration rate (eGFR) were assessed by non-parametric tests and regression analyses.
Median baseline GDF15 was 4744 pg/ml and 5451 pg/ml for the kidney transplantation and dialysis groups, respectively (p = 0.09). Kidney transplantation resulted in a significant decrease in GDF15 (month 12 median 1631 pg/ml, p < 0.0001 vs. baseline), whereas there was no change for the dialysis group (month 12 median 5658 pg/ml, p = 0.31). Post-kidney transplantation NT-proBNP highly correlated with GDF15 (ρ = 0.64, p < 0.0001). GDF15 inversely correlated with post-transplant eGFR for the kidney transplantation group (ρ = -0.42, p = 0.0081). Month 12 NT-proBNP explained 15.8% and 40.1% of the variance in month 12 GDF15 in the dialysis and kidney transplantation groups, respectively. The relationship of GDF15 with eGFR was no longer significant when NT-proBNP was included in the models.
Kidney transplantation significantly decreases serum GDF15 concentrations. The post-kidney transplantation association of GDF15 with NT-proBNP is consistent with a gradient of post- kidney transplantation cardiovascular risk.
生长分化因子 15(GDF15)在终末期肾病中显著增加,并与透析患者的死亡率增加有关。我们假设肾移植会降低 GDF15 和 N 末端 pro-B 型利钠肽(NT-proBNP)的水平,并且 GDF-15 的降低与肾移植后移植物功能有关。
在三个移植中心招募了 39 名正在接受活体供肾移植的终末期肾病透析患者,以及预计至少在 12 个月内等待死亡供体的 43 名患者。在肾移植或入组后 0、3 和 12 个月测量血清 GDF15 和 NT-proBNP。通过非参数检验和回归分析评估血清 GDF15 和 NT-proBNP 浓度的变化及其与估计肾小球滤过率(eGFR)的关系。
肾移植组和透析组的基线 GDF15 中位数分别为 4744pg/ml 和 5451pg/ml(p=0.09)。肾移植导致 GDF15 显著降低(第 12 个月中位数 1631pg/ml,p<0.0001 与基线相比),而透析组没有变化(第 12 个月中位数 5658pg/ml,p=0.31)。肾移植后 NT-proBNP 与 GDF15 高度相关(ρ=0.64,p<0.0001)。GDF15 与肾移植组的移植后 eGFR 呈负相关(ρ=-0.42,p=0.0081)。在透析组和肾移植组中,第 12 个月 NT-proBNP 分别解释了第 12 个月 GDF15 方差的 15.8%和 40.1%。当 NT-proBNP 包含在模型中时,GDF15 与 eGFR 的关系不再显著。
肾移植显著降低血清 GDF15 浓度。肾移植后 GDF15 与 NT-proBNP 的相关性与肾移植后心血管风险的梯度一致。